Third, consistent with the finding that mKras is a downstream target of DDX5 (Figure 3G), our recent studies demonstrated that human bladder cancer cells with mKras are more sensitive to FL118 treatment when compared to tumour cells with wild‐type Kras.80 The gene discussed is KRAS; the disease is urinary bladder cancer.